Trials / Completed
CompletedNCT06099184
Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- EyePoint Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept
Detailed description
A study to evaluate Efficacy and Safety of two doses of EYP-1901 in subjects with DME
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EYP-1901 | Intravitreal Injection |
| DRUG | Aflibercept 2Mg/0.05Ml Inj,Oph | Intravitreal Injection |
Timeline
- Start date
- 2024-01-15
- Primary completion
- 2024-10-24
- Completion
- 2024-10-24
- First posted
- 2023-10-25
- Last updated
- 2025-03-04
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06099184. Inclusion in this directory is not an endorsement.